BACKGROUND: We have developed a range of adenoviral (Ad) vectors based on human adenovirus serotype 5 (HAdV-5) displaying the fiber shaft and knob domains of species B viruses (HAdV-3, -11, or -35). These species B Ads utilize different cellular receptors than HAdV-5 for infection. We evaluated whether Ad vectors displaying species B fiber shaft and knob domains (Ad5F3Luc1, Ad5F11Luc1, and Ad5F35Luc1) would efficiently infect cancer cells of distinct origins, including prostate cancer. METHODS: The fiber chimeric Ad vectors were genetically generated and compared with the original Ad vector (Ad5Luc1) for transductional efficiency in a variety of cancer cell lines, including prostate cancer cells and primary prostate epithelial cells (PrEC), using luciferase as a reporter gene. RESULTS: Prostate cancer cell lines infected with Ad5F3Luc1 expressed higher levels of luciferase than Ad5Luc1, as well as the other chimeric Ad vectors. We also analyzed the transductional efficiency via monitoring of luciferase activity in prostate cancer cells when expressed as a fraction of the gene transfer in PrEC cells. In the PC-3 and DU145 cell lines, the gene transfer ratio of cancer cells versus PrEC was once again highest for Ad5F3Luc1. CONCLUSION: Of the investigated chimeric HAdV-5/species B vectors, Ad5F3Luc1 was judged to be the most suitable for targeting prostate cancer cells as it showed the highest transductional efficiency in these cells. It is foreseeable that an Ad vector incorporating the HAdV-3 fiber could potentially be used for prostate cancer gene therapy. Prostate 70: 362-376, 2010. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: We have developed a range of adenoviral (Ad) vectors based on human adenovirus serotype 5 (HAdV-5) displaying the fiber shaft and knob domains of species B viruses (HAdV-3, -11, or -35). These species B Ads utilize different cellular receptors than HAdV-5 for infection. We evaluated whether Ad vectors displaying species B fiber shaft and knob domains (Ad5F3Luc1, Ad5F11Luc1, and Ad5F35Luc1) would efficiently infect cancer cells of distinct origins, including prostate cancer. METHODS: The fiber chimeric Ad vectors were genetically generated and compared with the original Ad vector (Ad5Luc1) for transductional efficiency in a variety of cancer cell lines, including prostate cancer cells and primary prostate epithelial cells (PrEC), using luciferase as a reporter gene. RESULTS:Prostate cancer cell lines infected with Ad5F3Luc1 expressed higher levels of luciferase than Ad5Luc1, as well as the other chimeric Ad vectors. We also analyzed the transductional efficiency via monitoring of luciferase activity in prostate cancer cells when expressed as a fraction of the gene transfer in PrEC cells. In the PC-3 and DU145 cell lines, the gene transfer ratio of cancer cells versus PrEC was once again highest for Ad5F3Luc1. CONCLUSION: Of the investigated chimeric HAdV-5/species B vectors, Ad5F3Luc1 was judged to be the most suitable for targeting prostate cancer cells as it showed the highest transductional efficiency in these cells. It is foreseeable that an Ad vector incorporating the HAdV-3 fiber could potentially be used for prostate cancer gene therapy. Prostate 70: 362-376, 2010. (c) 2009 Wiley-Liss, Inc.
Authors: Dominique Sirena; Benjamin Lilienfeld; Markus Eisenhut; Stefan Kälin; Karin Boucke; Roger R Beerli; Lorenz Vogt; Christiane Ruedl; Martin F Bachmann; Urs F Greber; Silvio Hemmi Journal: J Virol Date: 2004-05 Impact factor: 5.103
Authors: Natalya Belousova; Nikolay Korokhov; Valentina Krendelshchikova; Vera Simonenko; Galina Mikheeva; Pierre L Triozzi; Wayne A Aldrich; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh Journal: J Virol Date: 2003-11 Impact factor: 5.103
Authors: Joshua J Short; Alexander V Pereboev; Yosuke Kawakami; Chenthamarakshan Vasu; Mark J Holterman; David T Curiel Journal: Virology Date: 2004-05-01 Impact factor: 3.616
Authors: Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent Journal: Mol Ther Date: 2010-02-23 Impact factor: 11.454
Authors: Patrick J Eulitt; Margaret A Park; Hamed Hossein; Nichola Cruikshanks; Chen Yang; Igor P Dmitriev; Adly Yacoub; David T Curiel; Paul B Fisher; Paul Dent Journal: Cancer Biol Ther Date: 2010-12-15 Impact factor: 4.742
Authors: Michael J Oneal; Miguel A Trujillo; Julia Davydova; Samantha McDonough; Masato Yamamoto; John C Morris Journal: Hum Gene Ther Date: 2012-08-22 Impact factor: 5.695
Authors: Anton V Borovjagin; Juan Dong; Michael J Passineau; Changchun Ren; Ejvis Lamani; Olga A Mamaeva; Hongju Wu; Enid Keyser; Miho Murakami; Shuo Chen; Mary MacDougall Journal: PLoS One Date: 2011-10-07 Impact factor: 3.240
Authors: Rupesh Dash; Sujit K Bhutia; Belal Azab; Zhao-zhong Su; Bridget A Quinn; Timothy P Kegelmen; Swadesh K Das; Keetae Kim; Seok-Geun Lee; Margaret A Park; Adly Yacoub; Mohammed Rahmani; Luni Emdad; Igor P Dmitriev; Xiang-Yang Wang; Devanand Sarkar; Steven Grant; Paul Dent; David T Curiel; Paul B Fisher Journal: Cytokine Growth Factor Rev Date: 2010-10 Impact factor: 7.638
Authors: Julius W Kim; Joel N Glasgow; Masaharu Nakayama; Ferhat Ak; Hideyo Ugai; David T Curiel Journal: PLoS One Date: 2013-02-01 Impact factor: 3.240